Piramal Enterprises Limited (PEL.NS)
INR 967.75
(2.1%)
INR 967.75
(2.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.83 Billion INR | -111.75% |
| 2022 | 143.33 Billion INR | 645.32% |
| 2021 | 19.23 Billion INR | 44.34% |
| 2020 | 13.32 Billion INR | 5444.49% |
| 2019 | 240.3 Million INR | -98.37% |
| 2018 | 14.73 Billion INR | -71.24% |
| 2017 | 51.21 Billion INR | 308.96% |
| 2016 | 12.52 Billion INR | 31.74% |
| 2015 | 9.5 Billion INR | -66.65% |
| 2014 | 28.49 Billion INR | 668.39% |
| 2013 | -5.01 Billion INR | -120.6% |
| 2012 | -2.27 Billion INR | -303.85% |
| 2011 | 1.11 Billion INR | -99.13% |
| 2010 | 128.83 Billion INR | 2573.45% |
| 2009 | 4.81 Billion INR | 52.38% |
| 2008 | 3.16 Billion INR | -5.25% |
| 2007 | 3.33 Billion INR | 53.07% |
| 2006 | 2.18 Billion INR | 80.73% |
| 2005 | 1.2 Billion INR | -26.46% |
| 2004 | 1.64 Billion INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.62 Billion INR | -10.2% |
| 2024 Q1 | 1.81 Billion INR | 32.38% |
| 2023 Q1 | 5.08 Billion INR | 994.48% |
| 2023 FY | -16.83 Billion INR | -111.75% |
| 2023 Q3 | -23.77 Billion INR | -5033.78% |
| 2023 Q2 | 481.9 Million INR | -90.53% |
| 2023 Q4 | 1.37 Billion INR | 105.77% |
| 2022 Q3 | 35.45 Billion INR | 330.76% |
| 2022 FY | 143.33 Billion INR | 645.32% |
| 2022 Q1 | 4.96 Billion INR | 353.22% |
| 2022 Q2 | -15.36 Billion INR | -409.7% |
| 2022 Q4 | -568.8 Million INR | -101.6% |
| 2021 FY | 19.23 Billion INR | 44.34% |
| 2021 Q3 | 8.55 Billion INR | 103.99% |
| 2021 Q1 | 5.39 Billion INR | 194.43% |
| 2021 Q4 | 1.09 Billion INR | -87.2% |
| 2021 Q2 | 4.19 Billion INR | -22.29% |
| 2020 Q4 | -5.71 Billion INR | -173.26% |
| 2020 FY | 13.32 Billion INR | 5444.49% |
| 2020 Q1 | 4.95 Billion INR | 129.12% |
| 2020 Q2 | 6.28 Billion INR | 26.79% |
| 2020 Q3 | 7.79 Billion INR | 24.09% |
| 2019 Q3 | 7.24 Billion INR | 30.7% |
| 2019 FY | 240.3 Million INR | -98.37% |
| 2019 Q2 | 5.54 Billion INR | 23.02% |
| 2019 Q4 | -17.01 Billion INR | -334.77% |
| 2019 Q1 | 4.5 Billion INR | -1.31% |
| 2018 FY | 14.73 Billion INR | -71.24% |
| 2018 Q2 | 4.81 Billion INR | 797.98% |
| 2018 Q1 | -689.4 Million INR | -101.75% |
| 2018 Q4 | 4.56 Billion INR | -24.36% |
| 2018 Q3 | 6.03 Billion INR | 25.52% |
| 2017 FY | 51.21 Billion INR | 308.96% |
| 2017 Q4 | 39.43 Billion INR | 703.38% |
| 2017 Q3 | 4.9 Billion INR | 27.84% |
| 2017 Q2 | 3.84 Billion INR | 26.89% |
| 2017 Q1 | 3.02 Billion INR | -2.68% |
| 2016 FY | 12.52 Billion INR | 31.74% |
| 2016 Q4 | 3.1 Billion INR | -23.04% |
| 2016 Q3 | 4.04 Billion INR | 31.9% |
| 2016 Q2 | 3.06 Billion INR | 32.66% |
| 2016 Q1 | 2.3 Billion INR | 19.61% |
| 2015 Q4 | 1.93 Billion INR | -39.99% |
| 2015 Q1 | 2.02 Billion INR | 112.52% |
| 2015 Q2 | 2.45 Billion INR | 21.29% |
| 2015 Q3 | 3.21 Billion INR | 30.82% |
| 2015 FY | 9.5 Billion INR | -66.65% |
| 2014 Q1 | 28.96 Billion INR | 1030.25% |
| 2014 Q4 | 954 Million INR | -61.69% |
| 2014 Q2 | -3.9 Billion INR | -113.49% |
| 2014 FY | 28.49 Billion INR | 668.39% |
| 2014 Q3 | 2.49 Billion INR | 163.72% |
| 2013 Q1 | -1.46 Billion INR | 26.82% |
| 2013 FY | -5.01 Billion INR | -120.6% |
| 2013 Q4 | -3.11 Billion INR | -2694.88% |
| 2013 Q3 | -111.4 Million INR | 65.47% |
| 2013 Q2 | -322.6 Million INR | 78.0% |
| 2012 Q4 | -2 Billion INR | -428.18% |
| 2012 Q2 | -920.2 Million INR | -2355.39% |
| 2012 Q1 | 40.8 Million INR | 110.55% |
| 2012 Q3 | 610.7 Million INR | 166.37% |
| 2012 FY | -2.27 Billion INR | -303.85% |
| 2011 Q3 | 85.2 Million INR | 0.0% |
| 2011 FY | 1.11 Billion INR | -99.13% |
| 2011 Q4 | -386.8 Million INR | -553.99% |
| 2010 FY | 128.83 Billion INR | 2573.45% |
| 2009 FY | 4.81 Billion INR | 52.38% |
| 2008 FY | 3.16 Billion INR | -5.25% |
| 2007 FY | 3.33 Billion INR | 53.07% |
| 2006 FY | 2.18 Billion INR | 80.73% |
| 2005 FY | 1.2 Billion INR | -26.46% |
| 2004 FY | 1.64 Billion INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 373.38% |
| Hester Biosciences Limited | 188.89 Million INR | 9012.753% |
| Aarti Drugs Limited | 1.71 Billion INR | 1082.119% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 876.171% |
| Albert David Limited | 754.2 Million INR | 2332.203% |
| Alembic Limited | 2.68 Billion INR | 726.735% |
| Alkem Laboratories Limited | 17.95 Billion INR | 193.75% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | 23011.716% |
| Bajaj HealthCare Limited | -837.93 Million INR | -1909.151% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 237484.377% |
| Brooks Laboratories Limited | -195.91 Million INR | -8492.99% |
| Eris Lifesciences Limited | 3.91 Billion INR | 529.491% |
| FDC Limited | 3.05 Billion INR | 651.573% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 457.522% |
| Gufic Biosciences Limited | 861.35 Million INR | 2054.511% |
| Hikal Limited | 696 Million INR | 2518.865% |
| Ind-Swift Limited | 142.31 Million INR | 11929.77% |
| Innova Captab Limited | 943.45 Million INR | 1884.44% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 1352.347% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 7594.68% |
| Jubilant Pharmova Limited | 771 Million INR | 2283.567% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | 1904.332% |
| Lupin Limited | 19.14 Billion INR | 187.937% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -18458.043% |
| Medico Remedies Limited | 82.9 Million INR | 20405.757% |
| Morepen Laboratories Limited | 961.59 Million INR | 1850.761% |
| Nectar Lifesciences Limited | 49.95 Million INR | 33804.304% |
| Orchid Pharma Limited | 921.66 Million INR | 1926.618% |
| Procter & Gamble Health Limited | 2 Billion INR | 937.66% |
| RPG Life Sciences Limited | 876.6 Million INR | 2020.522% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 11629.922% |
| Sigachi Industries Limited | 571.8 Million INR | 3044.253% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | -196.715% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 660.652% |
| Themis Medicare Limited | 435.23 Million INR | 3968.068% |
| Unichem Laboratories Limited | -704.74 Million INR | -2288.857% |
| Vaishali Pharma Limited | 7.18 Million INR | 234281.388% |
| Wanbury Limited | 559.56 Million INR | 3108.651% |
| Windlas Biotech Limited | 581.87 Million INR | 2993.31% |
| ZIM Laboratories Limited | 172.46 Million INR | 9861.631% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 499.925% |
| Ipca Laboratories Limited | 5.47 Billion INR | 407.578% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 117.58% |
| Venus Remedies Limited | 284.9 Million INR | 6009.03% |
| Sakar Healthcare Limited | 116.7 Million INR | 14525.023% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 153.058% |
| Divi's Laboratories Limited | 16 Billion INR | 205.221% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 1142.369% |
| Mankind Pharma Limited | 19.12 Billion INR | 188.009% |
| Sequent Scientific Limited | -358.69 Million INR | -4593.552% |
| Laurus Labs Limited | 1.6 Billion INR | 1148.602% |
| Neuland Laboratories Limited | 3 Billion INR | 661.029% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 404.641% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | -12.111% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 143.62% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 3843.457% |
| Wockhardt Limited | -4.63 Billion INR | -263.613% |
| Bal Pharma Limited | 73.92 Million INR | 22874.411% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 130.234% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 2331.198% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | 11709.751% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | 468.315% |
| Shilpa Medicare Limited | 318.74 Million INR | 5381.795% |
| Valiant Laboratories Limited | 3.19 Million INR | 526861.577% |
| Ajanta Pharma Limited | 8.16 Billion INR | 306.272% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | 36044.698% |
| Granules India Limited | 4.05 Billion INR | 515.368% |
| Medicamen Biotech Limited | 109.31 Million INR | 15501.427% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 6750.536% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 201.639% |
| NATCO Pharma Limited | 13.88 Billion INR | 221.266% |
| Suven Life Sciences Limited | -1.05 Billion INR | -1502.198% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | -8433.535% |
| Strides Pharma Science Limited | -706.14 Million INR | -2284.131% |
| Indoco Remedies Limited | 984.6 Million INR | 1809.86% |
| Alpa Laboratories Limited | 167.76 Million INR | 10135.049% |
| Lasa Supergenerics Limited | -217.3 Million INR | -7647.278% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | -334.78% |